Literature DB >> 23185001

Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin.

Luiz C Godoy1, Chase T M Anderson, Rajdeep Chowdhury, Laura J Trudel, Gerald N Wogan.   

Abstract

Melanoma patients experience inferior survival after biochemotherapy when their tumors contain numerous cells expressing the inducible isoform of NO synthase (iNOS) and elevated levels of nitrotyrosine, a product derived from NO. Although several lines of evidence suggest that NO promotes tumor growth and increases resistance to chemotherapy, it is unclear how it shapes these outcomes. Here we demonstrate that modulation of NO-mediated S-nitrosation of cellular proteins is strongly associated with the pattern of response to the anticancer agent cisplatin in human melanoma cells in vitro. Cells were shown to express iNOS constitutively, and to generate sustained nanomolar levels of NO intracellularly. Inhibition of NO synthesis or scavenging of NO enhanced cisplatin-induced apoptotic cell death. Additionally, pharmacologic agents disrupting S-nitrosation markedly increased cisplatin toxicity, whereas treatments favoring stabilization of S-nitrosothiols (SNOs) decreased its cytotoxic potency. Activity of the proapoptotic enzyme caspase-3 was higher in cells treated with a combination of cisplatin and chemicals that decreased NO/SNOs, whereas lower activity resulted from cisplatin combined with stabilization of SNOs. Constitutive protein S-nitrosation in cells was detected by analysis with biotin switch and reduction/chemiluminescence techniques. Moreover, intracellular NO concentration increased significantly in cells that survived cisplatin treatment, resulting in augmented S-nitrosation of caspase-3 and prolyl-hydroxylase-2, the enzyme responsible for targeting the prosurvival transcription factor hypoxia-inducible factor-1α for proteasomal degradation. Because activities of these enzymes are inhibited by S-nitrosation, our data thus indicate that modulation of intrinsic intracellular NO levels substantially affects cisplatin toxicity in melanoma cells. The underlying mechanisms may thus represent potential targets for adjuvant strategies to improve the efficacy of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23185001      PMCID: PMC3528548          DOI: 10.1073/pnas.1218938109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  NO: an inhibitor of cell death.

Authors:  L Liu; J S Stamler
Journal:  Cell Death Differ       Date:  1999-10       Impact factor: 15.828

Review 2.  Nitric oxide: NO apoptosis or turning it ON?

Authors:  Bernhard Brüne
Journal:  Cell Death Differ       Date:  2003-08       Impact factor: 15.828

3.  Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.

Authors:  S Ekmekcioglu; J Ellerhorst; C M Smid; V G Prieto; M Munsell; A C Buzaid; E A Grimm
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

4.  Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and fluids: implications for the fate of NO in vivo.

Authors:  Martin Feelisch; Tienush Rassaf; Sanie Mnaimneh; Nisha Singh; Nathan S Bryan; David Jourd'Heuil; Malte Kelm
Journal:  FASEB J       Date:  2002-11       Impact factor: 5.191

Review 5.  Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency.

Authors:  Keping Xie; Suyun Huang
Journal:  Free Radic Biol Med       Date:  2003-04-15       Impact factor: 7.376

6.  Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.

Authors:  D Massi; A Franchi; I Sardi; L Magnelli; M Paglierani; L Borgognoni; U Maria Reali; M Santucci
Journal:  J Pathol       Date:  2001-06       Impact factor: 7.996

7.  Antiapoptotic role of endogenous nitric oxide in human melanoma cells.

Authors:  O Salvucci; M Carsana; I Bersani; G Tragni; A Anichini
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

8.  Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells.

Authors:  Suhendan Ekmekcioglu; Julie A Ellerhorst; John B Mumm; Mingzhong Zheng; Lyle Broemeling; Victor G Prieto; Alexis L Stewart; Abner M Mhashilkar; Sunil Chada; Elizabeth A Grimm
Journal:  Mol Cancer Ther       Date:  2003-01       Impact factor: 6.261

9.  S-Nitrosylation of mitochondrial caspases.

Authors:  J B Mannick; C Schonhoff; N Papeta; P Ghafourifar; M Szibor; K Fang; B Gaston
Journal:  J Cell Biol       Date:  2001-09-10       Impact factor: 10.539

10.  Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.

Authors:  Christopher H Switzer; Robert Y-S Cheng; Lisa A Ridnour; Sharon A Glynn; Stefan Ambs; David A Wink
Journal:  Breast Cancer Res       Date:  2012-09-12       Impact factor: 6.466

View more
  22 in total

Review 1.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

Review 2.  Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide.

Authors:  Andrea Predonzani; Bianca Calì; Andrielly Hr Agnellini; Barbara Molon
Journal:  World J Exp Med       Date:  2015-05-20

Review 3.  Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.

Authors:  Elizabeth A Grimm
Journal:  Crit Rev Oncog       Date:  2016

4.  Nitric oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective.

Authors:  Birandra K Sinha
Journal:  J Cancer Sci Ther       Date:  2016-10-28

Review 5.  Updates of reactive oxygen species in melanoma etiology and progression.

Authors:  Feng Liu-Smith; Ryan Dellinger; Frank L Meyskens
Journal:  Arch Biochem Biophys       Date:  2014-04-26       Impact factor: 4.013

6.  Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model.

Authors:  Jonathan M Fahey; Joseph V Emmer; Witold Korytowski; Neil Hogg; Albert W Girotti
Journal:  Photochem Photobiol       Date:  2016-10-17       Impact factor: 3.421

7.  Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.

Authors:  Cristina Maccallini; Fabio Arias; Marialucia Gallorini; Pasquale Amoia; Alessandra Ammazzalorso; Barbara De Filippis; Marialuigia Fantacuzzi; Letizia Giampietro; Amelia Cataldi; María Encarnación Camacho; Rosa Amoroso
Journal:  ACS Med Chem Lett       Date:  2020-06-19       Impact factor: 4.345

8.  Role of Oxygen and Nitrogen Radicals in the Mechanism of Anticancer Drug Cytotoxicity.

Authors:  Birandra Kumar Sinha
Journal:  J Cancer Sci Ther       Date:  2020-01-24

9.  Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.

Authors:  Ashutosh Kumar; Marilyn Ehrenshaft; Erik J Tokar; Ronald P Mason; Birandra K Sinha
Journal:  Biochim Biophys Acta       Date:  2016-04-17

10.  Mechanism-based triarylphosphine-ester probes for capture of endogenous RSNOs.

Authors:  Uthpala Seneviratne; Luiz C Godoy; John S Wishnok; Gerald N Wogan; Steven R Tannenbaum
Journal:  J Am Chem Soc       Date:  2013-05-08       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.